(g) and (h) Industrial approvals for manufacture of bulk drugs are given only as per basic stages. Manufacture from late stage intermediates is permitted only in a few cases like Rifampicin, Pentazocin, Sulphadiazine, Pindalol, Ethambutol, Chloroquine Phosphate, Thioridazine etc. by giving relaxation to the basic stage, taking into consideration various reasons like technological constraints, economic viability etc.

Production of New Drugs

1604. SHRI H. HANUMANTHAPPA :
SHRI RAJNI RANJAN SAHU :
SHRIMATI SATYA BAHIN :

Will the PRIME MINISTER be pleased to state :

(a) what are the new bulk drugs produced by M/s. Parke Davis, Boots Pharmaceuticals, Roche Products, Hindustan Ciba Geigy, Duphar Interfran, Hoechst and Glaxo after the announcement of Drug Policy, 1986;

(b) what was the production from the date of commencement of production upto 31st October, 1992 year-wise and what is the stage of manufacture of each drug by each company;

(c) whether it is a fact that all these drugs are outside price control;

(d) what was the sales turnover, net fixed assets and profit before tax of each company year-wise after the announcement of Drug Policy, 1986;

(e) whether it is a fact that profits of these companies have gone up but no new investment has been made by these companies; and

(f) if so, what was the profits on sales turnover and on capital employed during these years ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) and (b) Since the announcement of the Drug Policy, 1986, Industrial Licences have been given to these companies for the manufacture of seven new drugs indicated in Annexure-I., along with the starting stages. [*See* Appendix CLXV, Annexure No. 29] Data in respect of production of Diclofenac Sodium and Ranitidine is available, which is given at Annexure-I.

(c) Of the seven drugs mentioned in Annexure-I, only Diclofenac Sodium and Ranitidine are under price control.

(d) to (f) The sales turnover, profits before tax and profits on sales turnover in respect of these companies, to the extent available, is given at Annexure-II. [*See* Appendix CLXV, Annexure No. 29]. The information on net fixed assets is not available. The profits/profitability of these companies have varied during this period. However these companies have been given approval for investments around Rs. 28.94 crores for the production of new drugs after the announcement of Drug Policy, 1986.

Increase in the Prices of Pyrental Pamoate

1605. SHRI HANUMANTHAPPA :
SHRI RAJNI RAJAN SAHU :
SHRIMATI SATYA BAHIN :

Will the PRIME MINISTER be pleased to state :

(a) whether it is a fact that the prices of Pyrental Pamoate was increased from Rs. 1282/- per Kg to Rs. 1346 - per Kg. based on interim price fixed under DPCO, 1979 for one year, if so, what are the reasons therefor;

(b) whether it is a fact that no cost study has been done hereafter although this drug is available at Rs. 900/- per Kg.

(c) what is the present notified price and when its price was increased and what were the basis on which the price was increased in the absence of cost study by BICP; and

(d) what steps have been taken to reduce the price ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) to (d) Under DPCO, 1987 BICP studied cost structure of Pyrental Pamoate and submitted its report in October, 1989. The continuation of price of this bulk drug at Rs. 1250 per kg. was notified on the basis of the above BICP report. The